{"id":"NCT04908683","sponsor":"Janssen Vaccines & Prevention B.V.","briefTitle":"A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older","officialTitle":"A Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of an Ad26.RSV.preF-based Vaccine in the Prevention of Lower Respiratory Tract Disease Caused by RSV in Adults Aged 60 Years and Older","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-07-21","primaryCompletion":"2023-07-21","completion":"2023-07-21","firstPosted":"2021-06-01","resultsPosted":"2024-02-08","lastUpdate":"2025-05-25"},"enrollment":25236,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Respiratory Syncytial Viruses","Lower Respiratory Tract Disease"],"interventions":[{"type":"BIOLOGICAL","name":"Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"Group 1: Respiratory Syncytial Virus (RSV) vaccine","type":"EXPERIMENTAL"},{"label":"Group 2: Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The study will enroll up to 27,200 participants in order to demonstrate the efficacy of the active Ad26.RSV.preF-based study vaccine in the prevention of Reverse Transcription Polymerase Chain Reaction (RT-PCR) confirmed Respiratory Syncytial Virus (RSV)-mediated Lower Respiratory Tract Disease (LRTD) when compared to placebo in adults aged 60 years and above.","primaryOutcome":{"measure":"Number of Participants With First Occurrence of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV) Mediated Lower Respiratory Tract Disease (LRTD)","timeFrame":"From Baseline (Day 1) up to 12 months","effectByArm":[{"arm":"Group 1: Ad26.RSV.preF and RSV preF Protein","deltaMin":44,"sd":null},{"arm":"Group 2: Placebo","deltaMin":63,"sd":null}],"pValues":[]},"eligibility":{"minAge":"60 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":272,"countries":["United States","Australia","Brazil","Canada","Chile","China","Estonia","Finland","New Zealand","Poland","South Africa","Taiwan","Thailand","United Kingdom"]},"refs":{"pmids":["38902186"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":842,"n":16709},"commonTop":["Vaccination Site Pain(Solicited)","Fatigue(Solicited)","Myalgia(Solicited)","Headache(Solicited)","Nausea(Solicited)"]}}